JP6139712B2 - Ｇｌｐ−１様ペプチドの誘導体及びその使用 - Google Patents

Ｇｌｐ−１様ペプチドの誘導体及びその使用 Download PDF

Info

Publication number: JP6139712B2
Authority: JP; Japan
Prior art keywords: xaa; derivative; lys; glp; chem
Prior art date: 2013-07-04
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Active

Application number

JP2015563070A

Other languages

English (en)

Japanese (ja)

Other versions

JP2016528163A (ja

Inventor

ステフェン・リーツ−ルンゲ

ヤコブ・コフォード

クリスティアン・ヴェンゼル・トーノエ

ペル・サウアーベア

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Novo Nordisk AS

Original Assignee

Novo Nordisk AS

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2013-07-04

Filing date

2014-07-02

Publication date

2017-05-31

2014-07-02 Application filed by Novo Nordisk AS filed Critical Novo Nordisk AS

2016-09-15 Publication of JP2016528163A publication Critical patent/JP2016528163A/ja

2017-05-31 Application granted granted Critical

2017-05-31 Publication of JP6139712B2 publication Critical patent/JP6139712B2/ja

Status Active legal-status Critical Current

2034-07-02 Anticipated expiration legal-status Critical

Links

0 *N[C@@](CCCCNC(COCCOCCNC(COCCOCCNC(CC[C@@](C(O)=O)N*(C1CCC(CNC(CCCCCCCCCCCCCCCCCCC(O)=O)=O)CC1)=O)=O)=O)=O)C(O)=O Chemical compound *N[C@@](CCCCNC(COCCOCCNC(COCCOCCNC(CC[C@@](C(O)=O)N*(C1CCC(CNC(CCCCCCCCCCCCCCCCCCC(O)=O)=O)CC1)=O)=O)=O)=O)C(O)=O 0.000 description 3
SBKZDKNILFDKCR-UHFFFAOYSA-N NC(CCC(NCCOCCOCCNN)=O)=O Chemical compound NC(CCC(NCCOCCOCCNN)=O)=O SBKZDKNILFDKCR-UHFFFAOYSA-N 0.000 description 2
PTBDJYCLPVMEHR-UHFFFAOYSA-N NC(CCCCCCCCCCCCCCCCCCC(O)=O)=O Chemical compound NC(CCCCCCCCCCCCCCCCCCC(O)=O)=O PTBDJYCLPVMEHR-UHFFFAOYSA-N 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/545—Heterocyclic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Endocrinology (AREA)
Epidemiology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Diabetes (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Zoology (AREA)
Gastroenterology & Hepatology (AREA)
Immunology (AREA)
Hematology (AREA)
Obesity (AREA)
Urology & Nephrology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Toxicology (AREA)
Genetics & Genomics (AREA)
Addiction (AREA)
Dermatology (AREA)
Physical Education & Sports Medicine (AREA)
Rheumatology (AREA)
Psychiatry (AREA)

JP2015563070A 2013-07-04 2014-07-02 Ｇｌｐ−１様ペプチドの誘導体及びその使用 Active JP6139712B2 (ja)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
EP13175094		2013-07-04
EP13175094.5		2013-07-04
US201361845646P	2013-07-12	2013-07-12
US61/845,646		2013-07-12
PCT/EP2014/064033 WO2015000942A1 (en)	2013-07-04	2014-07-02	Derivatives of glp-1 like peptides, and uses thereof

Related Child Applications (1)

Application Number	Title	Priority Date	Filing Date
JP2017022249A Division JP6687557B2 (ja)	2013-07-04	2017-02-09	Ｇｌｐ−１様ペプチドの誘導体及びその使用

Publications (2)

Publication Number	Publication Date
JP2016528163A JP2016528163A (ja)	2016-09-15
JP6139712B2 true JP6139712B2 (ja)	2017-05-31

Family

ID=48703344

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
JP2015563070A Active JP6139712B2 (ja)	2013-07-04	2014-07-02	Ｇｌｐ−１様ペプチドの誘導体及びその使用
JP2017022249A Active JP6687557B2 (ja)	2013-07-04	2017-02-09	Ｇｌｐ−１様ペプチドの誘導体及びその使用

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
JP2017022249A Active JP6687557B2 (ja)	2013-07-04	2017-02-09	Ｇｌｐ−１様ペプチドの誘導体及びその使用

Country Status (11)

Country	Link
US (2)	US9498534B2 (2)
EP (1)	EP3016975B1 (2)
JP (2)	JP6139712B2 (2)
KR (1)	KR20160029079A (2)
CN (1)	CN105377884B (2)
AR (1)	AR096789A1 (2)
AU (1)	AU2014286234A1 (2)
BR (1)	BR112015032875A2 (2)
CA (1)	CA2916311A1 (2)
MX (1)	MX2015016875A (2)
WO (1)	WO2015000942A1 (2)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP6475233B2 (ja)	2013-06-20	2019-02-27	ノヴォノルディスクアー／エス	Ｇｌｐ−１誘導体及びその使用
EP3016975B1 (en) *	2013-07-04	2019-01-16	Novo Nordisk A/S	Derivatives of glp-1 like peptides, and uses thereof
JP6730278B2 (ja)	2014-11-27	2020-07-29	ノヴォノルディスクアー／エス	Ｇｌｐ−１誘導体及びその使用
WO2016097108A1 (en)	2014-12-17	2016-06-23	Novo Nordisk A/S	Glp-1 derivatives and uses thereof
AU2016270373A1 (en)	2015-06-05	2018-01-04	Vertex Pharmaceuticals Incorporated	Triazoles for the treatment of demyelinating diseases
CN108697768B (zh)	2015-12-23	2022-07-22	约翰霍普金斯大学	长效glp-1r激动剂作为神经系统病状和神经退行性病状的治疗方法
US10946074B2 (en)	2016-03-03	2021-03-16	Novo Nordisk A/S	GLP-1 derivatives and uses thereof
ES2828526T3 (es)	2016-11-07	2021-05-26	Novo Nordisk As	Esteres activos DCHBS de compuestos PEG y sus usos
WO2018106646A1 (en)	2016-12-06	2018-06-14	Vertex Pharmaceuticals Incorporated	Aminotriazoles for the treatment of demyelinating diseases
WO2018106641A1 (en)	2016-12-06	2018-06-14	Vertex Pharmaceuticals Incorporated	Pyrazoles for the treatment of demyelinating diseases
WO2018106643A1 (en)	2016-12-06	2018-06-14	Vertex Pharmaceuticals Incorporated	Heterocyclic azoles for the treatment of demyelinating diseases
CN108976147B (zh) *	2017-05-31	2021-02-12	首都医科大学	氨基正己酰氨基甲环酰氨基正己酰碱性氨基酸，其合成，活性和应用
CN109248323B (zh) *	2017-07-14	2023-09-08	杭州先为达生物科技有限公司	酰化的glp-1衍生物
CA3068956A1 (en)	2017-07-19	2019-01-24	Novo Nordisk A/S	Bifunctional compounds
KR102665710B1 (ko)	2017-08-24	2024-05-14	노보 노르디스크 에이/에스	Glp-1 조성물 및 그 용도
JP7359358B2 (ja) *	2017-11-30	2023-10-11	グリアファームエスエー	神経疾患の予防及び治療に使用するためのポリケチド化合物及びその誘導体
MX2020010505A (es)	2018-04-05	2021-01-15	Sun Pharmaceutical Ind Ltd	Analogos novedosos de glp-1.
CN110386974B (zh) *	2018-04-19	2022-12-09	杭州先为达生物科技有限公司	Glp-1衍生物及其治疗用途
CN113214381B (zh) *	2018-04-19	2024-01-19	杭州先为达生物科技股份有限公司	酰化的glp-1衍生物
WO2019200594A1 (zh)	2018-04-19	2019-10-24	杭州先为达生物科技有限公司	酰化的glp-1衍生物
DE112018007827T5 (de) *	2018-07-12	2021-03-25	Mitsubishi Electric Corporation	Halbleitervorrichtung
EP4085077A4 (en)	2019-12-31	2024-01-17	Beijing QL Biopharmaceutical Co., Ltd.	Fusion proteins of glp-1 and gdf15 and conjugates thereof
CN113728013B (zh)	2020-01-11	2022-06-14	北京质肽生物医药科技有限公司	Glp-1和fgf21的融合蛋白的缀合物
JP7761567B2 (ja) *	2020-02-18	2025-10-28	ノヴォノルディスクアー／エス	医薬製剤
CN114729060B (zh)	2020-09-30	2022-11-25	北京质肽生物医药科技有限公司	多肽缀合物和使用方法
CN116490212A (zh) *	2020-11-06	2023-07-25	诺和诺德股份有限公司	Glp-1前药及其用途
CN114685644A (zh) *	2020-12-29	2022-07-01	苏州康宁杰瑞生物科技有限公司	一种人glp-1多肽变体及其应用
WO2023284822A1 (en)	2021-07-14	2023-01-19	Beijing Ql Biopharmaceutical Co., Ltd.	Fusion polypeptides for metabolic disorders
EP4323413A4 (en)	2022-03-30	2025-10-15	Beijing Ql Biopharmaceutical Co Ltd	LIQUID PHARMACEUTICAL COMPOSITIONS OF POLYPEPTIDE CONJUGATES AND METHODS OF USE THEREOF
JP2026502943A (ja)	2022-12-30	2026-01-27	アルギファルマエーエス	経口投与されるポリペプチド治療剤の全身バイオアベイラビリティを高める組成物および方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6458924B2 (en) *	1996-08-30	2002-10-01	Novo Nordisk A/S	Derivatives of GLP-1 analogs
WO1999043706A1 (en) *	1998-02-27	1999-09-02	Novo Nordisk A/S	Derivatives of glp-1 analogs
CZ20013018A3 (cs)	1999-03-17	2002-02-13	Novo Nordisk A/S	Způsob pro acylování aminoskupiny peptidu nebo proteinu a sloučenina
EP1076066A1 (en) *	1999-07-12	2001-02-14	Zealand Pharmaceuticals A/S	Peptides for lowering blood glucose levels
AU1269501A (en)	1999-11-12	2001-05-30	Novo Nordisk A/S	Use of glp-1 agonists for the inhibition of beta cell degeneration
GB0020551D0 (en)	2000-08-22	2000-10-11	Birkett David	Sprinkler system
JP2006520818A (ja)	2003-03-19	2006-09-14	イーライリリーアンドカンパニー	ポリエチレングリコール結合ｇｌｐ−１化合物
TWI362392B (en)	2005-03-18	2012-04-21	Novo Nordisk As	Acylated glp-1 compounds
CA2608311C (en)	2005-05-13	2012-11-27	Eli Lilly And Company	Glp-1 pegylated compounds
US20110144010A1 (en)	2007-06-01	2011-06-16	Novo Nordisk A/S	Spontaneously Dispersible Preconcentrates Including a Peptide Drug in a Solid or Semisolid Carrier
EP2190872B1 (en)	2007-09-05	2018-03-14	Novo Nordisk A/S	Glucagon-like peptide-1 derivatives and their pharmaceutical use
WO2009030771A1 (en)	2007-09-05	2009-03-12	Novo Nordisk A/S	Peptides derivatized with a-b-c-d- and their therapeutical use
US20100317057A1 (en)	2007-12-28	2010-12-16	Novo Nordisk A/S	Semi-recombinant preparation of glp-1 analogues
ES2401965T3 (es)	2009-02-19	2013-04-25	Novo Nordisk A/S	Modificación de Factor VIII
JP6006118B2 (ja) *	2009-12-16	2016-10-12	ノヴォノルディスクアー／エス	Ｇｌｐ−１アナログ及び誘導体
JP6039569B2 (ja)	2010-11-09	2016-12-07	ノヴォノルディスクアー／エス	二重アシル化されたｇｌｐ−１誘導体
PL2696687T3 (pl)	2011-04-12	2017-06-30	Novo Nordisk A/S	Pochodne podwójnie acylowanej GLP-1
EP3016975B1 (en) *	2013-07-04	2019-01-16	Novo Nordisk A/S	Derivatives of glp-1 like peptides, and uses thereof

2014
- 2014-07-02 EP EP14734816.3A patent/EP3016975B1/en active Active
- 2014-07-02 CA CA2916311A patent/CA2916311A1/en not_active Withdrawn
- 2014-07-02 BR BR112015032875A patent/BR112015032875A2/pt not_active Application Discontinuation
- 2014-07-02 JP JP2015563070A patent/JP6139712B2/ja active Active
- 2014-07-02 AU AU2014286234A patent/AU2014286234A1/en not_active Abandoned
- 2014-07-02 AR ARP140102467A patent/AR096789A1/es unknown
- 2014-07-02 WO PCT/EP2014/064033 patent/WO2015000942A1/en not_active Ceased
- 2014-07-02 CN CN201480038380.6A patent/CN105377884B/zh active Active
- 2014-07-02 KR KR1020167002151A patent/KR20160029079A/ko not_active Withdrawn
- 2014-07-02 MX MX2015016875A patent/MX2015016875A/es unknown
- 2014-07-02 US US14/322,077 patent/US9498534B2/en active Active
2016
- 2016-09-28 US US15/278,501 patent/US10010614B2/en active Active
2017
- 2017-02-09 JP JP2017022249A patent/JP6687557B2/ja active Active

Also Published As

Publication number	Publication date
US10010614B2 (en)	2018-07-03
CA2916311A1 (en)	2015-01-08
JP2016528163A (ja)	2016-09-15
EP3016975A1 (en)	2016-05-11
CN105377884A (zh)	2016-03-02
US9498534B2 (en)	2016-11-22
AU2014286234A1 (en)	2015-12-17
US20170007707A1 (en)	2017-01-12
MX2015016875A (es)	2016-04-07
CN105377884B (zh)	2021-07-20
EP3016975B1 (en)	2019-01-16
KR20160029079A (ko)	2016-03-14
JP2017105819A (ja)	2017-06-15
WO2015000942A1 (en)	2015-01-08
JP6687557B2 (ja)	2020-04-22
AR096789A1 (es)	2016-02-03
BR112015032875A2 (pt)	2017-11-07
US20150011462A1 (en)	2015-01-08

Legal Events

Date	Code	Title	Description
2016-05-24	A521	Request for written amendment filed	Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160222
2016-05-24	A621	Written request for application examination	Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20160222
2016-05-24	A871	Explanation of circumstances concerning accelerated examination	Free format text: JAPANESE INTERMEDIATE CODE: A871 Effective date: 20160222
2016-07-01	A975	Report on accelerated examination	Free format text: JAPANESE INTERMEDIATE CODE: A971005 Effective date: 20160630
2016-07-11	A131	Notification of reasons for refusal	Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20160711
2016-10-11	A521	Request for written amendment filed	Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20161011
2016-11-28	A02	Decision of refusal	Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20161128
2017-02-09	A521	Request for written amendment filed	Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170209
2017-02-17	A911	Transfer to examiner for re-examination before appeal (zenchi)	Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20170216
2017-03-29	TRDD	Decision of grant or rejection written
2017-04-03	A01	Written decision to grant a patent or to grant a registration (utility model)	Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20170403
2017-05-08	A61	First payment of annual fees (during grant procedure)	Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20170427
2017-05-12	R150	Certificate of patent or registration of utility model	Ref document number: 6139712 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150
2020-05-01	R250	Receipt of annual fees	Free format text: JAPANESE INTERMEDIATE CODE: R250
2021-05-06	R250	Receipt of annual fees	Free format text: JAPANESE INTERMEDIATE CODE: R250
2022-04-28	R250	Receipt of annual fees	Free format text: JAPANESE INTERMEDIATE CODE: R250
2023-04-28	R250	Receipt of annual fees	Free format text: JAPANESE INTERMEDIATE CODE: R250
2024-05-07	R250	Receipt of annual fees	Free format text: JAPANESE INTERMEDIATE CODE: R250
2025-05-09	R250	Receipt of annual fees	Free format text: JAPANESE INTERMEDIATE CODE: R250

Publication	Publication Date	Title
JP6139712B2 (ja)	2017-05-31	Ｇｌｐ−１様ペプチドの誘導体及びその使用
JP6475233B2 (ja)	2019-02-27	Ｇｌｐ−１誘導体及びその使用
JP6599863B2 (ja)	2019-10-30	Ｇｌｐ−１誘導体及びその使用
JP6730278B2 (ja)	2020-07-29	Ｇｌｐ−１誘導体及びその使用
JP6250034B2 (ja)	2017-12-20	二重アシル化されたｇｌｐ−１誘導体
JP6691125B2 (ja)	2020-04-28	Ｇｌｐ−１誘導体及びその使用
CN105601729A (zh)	2016-05-25	双-酰化的glp-1衍生物
TW201529598A (zh)	2015-08-01	類ｇｌｐ－１胜肽之衍生物及其用途